244 related articles for article (PubMed ID: 29292224)
1. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R
Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224
[TBL] [Abstract][Full Text] [Related]
2. Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes.
Ettari R; Cerchia C; Maiorana S; Guccione M; Novellino E; Bitto A; Grasso S; Lavecchia A; Zappalà M
ChemMedChem; 2019 Apr; 14(8):842-852. PubMed ID: 30829448
[TBL] [Abstract][Full Text] [Related]
3. Development of isoquinolinone derivatives as immunoproteasome inhibitors.
Ettari R; Iraci N; Di Chio C; Previti S; Danzè M; Zappalà M
Bioorg Med Chem Lett; 2022 Jan; 55():128478. PubMed ID: 34838650
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
5. Virtual Screening Strategy and In Vitro Tests to Identify New Inhibitors of the Immunoproteasome.
Culletta G; Tutone M; Ettari R; Perricone U; Di Chio C; Almerico AM; Zappalà M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445688
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
7. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
[TBL] [Abstract][Full Text] [Related]
8. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
[TBL] [Abstract][Full Text] [Related]
9. Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.
Singh PK; Fan H; Jiang X; Shi L; Nathan CF; Lin G
ChemMedChem; 2016 Oct; 11(19):2127-2131. PubMed ID: 27561172
[TBL] [Abstract][Full Text] [Related]
10. Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
Ettari R; Pallio G; Pizzino G; Irrera N; Zappalà M; Maiorana S; Di Chio C; Altavilla D; Squadrito F; Bitto A
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1307-1313. PubMed ID: 31307247
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.
Maurits E; Degeling CG; Kisselev AF; Florea BI; Overkleeft HS
Chembiochem; 2020 Nov; 21(22):3220-3224. PubMed ID: 32598532
[TBL] [Abstract][Full Text] [Related]
12. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
13. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening.
Scarpino A; Bajusz D; Proj M; Gobec M; Sosič I; Gobec S; Ferenczy GG; Keserű GM
Molecules; 2019 Jul; 24(14):. PubMed ID: 31315311
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
[TBL] [Abstract][Full Text] [Related]
16. Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
Nan G; Huang L; Li Y; Yang Y; Yang Y; Li K; Lai F; Chen X; Xiao Z
Eur J Med Chem; 2022 Apr; 234():114252. PubMed ID: 35286927
[TBL] [Abstract][Full Text] [Related]
17. Argyrin B, a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i.
Allardyce DJ; Bell CM; Loizidou EZ
Chem Biol Drug Des; 2019 Aug; 94(2):1556-1567. PubMed ID: 31074944
[TBL] [Abstract][Full Text] [Related]
18. A Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome Inhibitors.
Groll M; Korotkov VS; Huber EM; de Meijere A; Ludwig A
Angew Chem Int Ed Engl; 2015 Jun; 54(27):7810-4. PubMed ID: 25973989
[TBL] [Abstract][Full Text] [Related]
19. Immunoproteasome inhibition and bioactivity of thiasyrbactins.
Bakas NA; Schultz CR; Yco LP; Roberts CC; Chang CA; Bachmann AS; Pirrung MC
Bioorg Med Chem; 2018 Jan; 26(2):401-412. PubMed ID: 29269255
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes.
Xin BT; de Bruin G; Huber EM; Besse A; Florea BI; Filippov DV; van der Marel GA; Kisselev AF; van der Stelt M; Driessen C; Groll M; Overkleeft HS
J Med Chem; 2016 Aug; 59(15):7177-87. PubMed ID: 27438186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
